

REVERSE News

Newsletter Issue 2, May 2022

REVERSE AT A GLANCE

REVERSE (pREvention and management tools for rEducing antibiotic Resistance in high prevalence SETTINGS) is an EU Horizon 2020 project running from July 2021 for 5 years.



Emerging antibiotic resistance has become a serious problem not only in Europe but globally. The development and implementation of **effective prevention and control strategies** are a crucial component in combatting **antimicrobial resistance (AMR)**. Rather than in separate studies, the goal of reducing AMR in acute care hospitals can only be optimally achieved in a **collaborative approach** where various activities interact together in a large clinical trial that is sufficiently powered to provide

actionable outcomes.

REVERSE focusses on AMR in acute care hospitals in **Greece, Italy, Romania and Spain**. It uses a **mixed-methods approach** combining quantitative research with implementation science and economic analysis. In a sufficiently powered **clinical trial**, REVERSE will answer the question about the real-life effectiveness of infection prevention and control programmes in combination with antibiotic stewardship on healthcare-associated infections due to multidrug-resistant microorganisms: an implementation study that has not been done at this level and scope before.

To achieve this goal, **REVERSE** is supported by a strong consortium from academia, healthcare organisations and governmental bodies, including **12 beneficiaries** from Greece, Israel, Italy, the Netherlands, Romania, Spain, Switzerland and the United Kingdom, as well as a total of **24 acute care hospitals** in the four southern European countries. REVERSE is led by the coordinating entity **University of Zurich (Switzerland)**, with **PD Dr Walter Zingg** as the coordinator.

Microbiology and Diagnostic Stewardship (MDS) Programme




Infection Prevention & Control (IPC) Programme



Antibiotic Stewardship (ABS) Programme



Integrated, evidence-based, modular strategy with complementary intervention programmes for reducing the clinical burden of infections caused by multidrug-resistant (MDR) bacteria in high prevalence settings.



In This Issue

REVERSE at a Glance

Project Consortium

Work Package Spotlight

News

Website and Social Media:

www.reverseproject.eu




Contact us:

PD Dr Walter Zingg
REVERSE Coordinator

reverse@usz.ch

Tel: +41 (0)44 255 8634

PROJECT CONSORTIUM



WORK PACKAGE SPOTLIGHT


Work Package 2: Microbiology and Diagnostic Stewardship Programme

Work Package 2 deals with the **microbiology and diagnostics capacity** at the 24 acute care REVERSE hospitals in Greece, Italy, Romania and Spain. The main objectives of Work Package 2 are to **improve microbiological diagnostics** at the local level in the participating hospitals to detect CRE, CRPA and CRAB, and to **determine the prevalence of CRO and their clonal relatedness** by performing repeated, standardised prevalence surveys of CRO and their molecular characteristics.

An **auditing tool** to identify the microbiology capacity and suggest measures to improve the capacity has been developed over the first 9 months of the project and is currently applied by the participating hospitals. A **quality control system** was established in REVERSE by sending out strains to the participating hospitals.

Prevalence surveys on CRO colonisation will be conducted at three time points over the project lifetime, **starting in early 2023** at the first randomised hospitals.

To learn more about and to stay up-to-date with new developments in Work Package 2, check out the **REVERSE website**.



Clinical study at the centre of the REVERSE project officially kicked off

Benefits from hospital involvement from different perspectives



REVERSE Hospitals



REVERSE Beneficiaries & Scientific Advisory Board

The **clinical study** in REVERSE kicked off with a meeting between the REVERSE consortium and the 24 participating hospitals on 23 February 2022. This **stepped-wedge, cluster-randomised clinical study** on the effectiveness of microbiology and diagnostic stewardship, infection prevention and control, and antibiotic stewardship will run for 4 years.

The focus of the meeting was on introducing the hospitals and providing an overview of the scientific work programme, as well as training activities. The clinical study started with the **collection of data on healthcare-associated infection surveillance**. Learn more about the REVERSE clinical study [here](#).



REVERSE Clinical Study Kick-Off Meeting, 23 February 2022, Online

2

Annual REVERSE Project Meeting 2022

The first **Annual REVERSE Project Meeting** was conducted on 26-27 April 2022. It was a hybrid meeting, with participants in person at the meeting venue in Lisbon (Portugal). The meeting was conducted just after the end of the **ECCMID-22 conference**.

Following on the welcome note by REVERSE coordinator PD Dr Walter Zingg from the University of Zurich, all Work Package leads presented their progress and work planned for the upcoming year. Also, the REVERSE General Assembly conducted a hybrid meeting.

Learn more about the Annual REVERSE Project Meeting 2022 [here](#).



Media coverage of REVERSE

The **REVERSE Clinical Study Kick-Off Meeting** as the official start of the clinical study in REVERSE on 23 February 2022 was covered by news articles on the **REVERSE website** and the website of **ID-CARE (Infectious Diseases Center for trAnslational Research)**.

More REVERSE news can be found on the **REVERSE website** in the *Dissemination* section.

UNSUBSCRIBE

www.reverseproject.eu

Follow us on



REVERSE has received funding from the European Union's 2020 research and innovation programme under grant agreement No 965265.

The content of this newsletter reflects only the author's view. The European Commission is not responsible for any use that may be made of the information it contains.